AVEO RCC

This study will be comparing tivozanib in combination with nivolumab to tivozanib alone in subjects with advanced Renal Cell Carcinoma (RCC) who have had 1 or 2 prior lines of therapy, one of which was an Immune Checkpoint Inhibitor (ICI).

Acronym:

TiNivo-2

ACTRN/NCT /ethics:

NCT04987203

Scientific title:

TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma who have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor

Sponsor / Cooperative group:

AVEO Pharmaceuticals, Inc.